Ichnos Glenmark and AbbVie Join Forces for ISB 2001
In a groundbreaking move in the biotech industry, Ichnos Glenmark Innovation (IGI) and AbbVie have forged an exclusive global licensing agreement to develop ISB 2001, a first-in-class trispecific antibody. This innovative therapeutic is currently undergoing a Phase 1 clinical trial aimed at providing new options for patients suffering from relapsed/refractory multiple myeloma (R/R MM).
What is ISB 2001?
ISB 2001 is designed to engage multiple targets to enhance anti-tumor activity. By targeting BCMA and CD38 on myeloma cells, as well as CD3 on T cells, it aims to engage the immune system more effectively than traditional therapies. This trispecific approach represents a promising advancement in cancer treatment, potentially leading to improved responses in difficult-to-treat patient populations.
The Significance of the Licensing Agreement
The collaboration highlights the commitment of both companies to innovate in the realm of immuno-oncology. AbbVie, which is known for its pioneering work in therapeutic development, views this partnership as an instrumental step in providing novel treatments for patients affected by multiple myeloma. Roopal Thakkar, M.D., AbbVie's Executive Vice-President of Research and Development, emphasized the potential of multispecific therapies, noting their ability to provide more profound and lasting treatment responses by targeting multiple pathways.
Financial Terms and Potential
Under the terms of the agreement, AbbVie will gain exclusive rights to develop, manufacture, and commercialize ISB 2001 across key global markets including North America, Europe, Japan, and Greater China. IGI is set to receive an upfront payment of $700 million, with the potential for additional payments nearing $1.225 billion depending on development, regulatory milestones, and commercial sales. This partnership not only accelerates the development timeline for ISB 2001 but also enhances IGI's focus on advancing its innovative pipeline.
Clinical Trial Results for ISB 2001
Recent clinical trial data presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting showed promising results for ISB 2001. In a cohort of 35 heavily pretreated patients, the overall response rate was an impressive 79%, with a notable complete response rate of 30% at doses of 50 µg/kg or more. These outcomes underscore the potential of ISB 2001 to deliver significant clinical benefits for patients battling major health challenges.
The BEAT® Protein Platform
ISB 2001 has been developed using IGI's proprietary BEAT® protein platform, which enhances the ability to create multispecific antibodies. This technology addresses the limitations faced by traditional bispecific approaches, particularly in producing stable and effective treatments at scale. By facilitating the development of robust immune cell engagers, the BEAT® platform is positioned to revolutionize the field of oncology.
About the Collaborating Companies
IGI is a global, fully integrated clinical-stage biotechnology company with a focus on pioneering biologics aimed at treating complex diseases. With its headquarters in New York, IGI utilizes its BEAT® technology platform to advance innovative therapies that aim to improve patient outcomes in hematological malignancies and solid tumors.
AbbVie's Commitment to Oncology
AbbVie is dedicated to discovering and delivering transformative therapies that address serious health challenges today, while preparing for future medical needs. With a robust pipeline that includes over 35 investigational medicines aimed at various cancer types, AbbVie remains at the forefront of oncology innovation. Their commitment encompasses not only the creation of effective medications but also efforts to ensure patient access to these solutions.
Frequently Asked Questions
What is ISB 2001?
ISB 2001 is a trispecific antibody designed for the treatment of relapsed/refractory multiple myeloma, targeting BCMA, CD38, and CD3.
What is the significance of the partnership?
The partnership between IGI and AbbVie enhances the development of ISB 2001, providing both financial support and bolstering scientific collaboration.
What were the recent outcomes of the clinical trial?
The Phase 1 trial of ISB 2001 reported a 79% overall response rate and a 30% complete response rate among heavily pretreated patients.
What is the BEAT® platform?
The BEAT® platform is IGI's innovative technology that allows for the creation of multispecific antibodies, enhancing treatment options through improved stability and efficacy.
How does AbbVie view this collaboration?
AbbVie sees the partnership as an opportunity to pioneer new therapies for challenging health conditions like multiple myeloma, aligning with their commitment to patient care.
